- PR Newswire•1 hour agoAbbott Receives FDA Approval for the FreeStyle Libre Pro™ System, a Revolutionary Diabetes Sensing Technology for Healthcare Professionals to Use with Their Patients
ABBOTT PARK, Ill., Sept. 28, 2016 /PRNewswire/ -- Abbott (ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's FreeStyle Libre Pro system, a revolutionary continuous glucose monitoring (CGM) system for healthcare professionals to use with their patients with diabetes. FreeStyle Libre Pro system is designed to empower healthcare professionals to provide better diabetes management for diabetes patients. The system provides healthcare professionals with a visual snapshot of glucose data, known as the Ambulatory Glucose Profile (AGP), giving a more simplified and clear overview of not only glucose levels, but also patterns and trends within those levels.
- Zacks•2 days ago
AbbVie Inc. (ABBV) announced positive results from the phase IIIb study, Garnet, on a combination of its hepatitis drugs Viekirax and Exviera for the treatment of patients with hepatitis C virus (HCV) infection without liver cirrhosis.
- Market Realist•5 days ago
On September 16, 2016, Johnson & Johnson announced the acquisition of Abbott Medical Optics, a subsidiary of Abbott Laboratories, and its stock fell ~0.3%.
Abbott Laboratories (ABT)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||42.24 x 2700|
|Ask||42.25 x 200|
|Day's Range||42.06 - 42.53|
|52wk Range||36.00 - 46.38|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||27.83|
|Avg Vol (3m)||9,620,365|
|Dividend & Yield||1.04 (2.50%)|